We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
07 November 2018
The Patented Medicine Prices Review Board (PMPRB) has released its fourth edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2016/17. The report was prepared as part of the National Prescription Drug Utilisation Information System (NPDUIS) and examines public drug plan expenditures in Canada, including analysing the main factors that drive annual changes in prescription drug expenditures.
The PMPRB has also released the 2017 Supplement to the Market Intelligence Report, Biologic Response Modifier Agents 2015, both produced under the NPDUIS initiative. Using data from 2017, the supplement provides updated information for market trends analysed in the original report, which focuses on certain biologics that the report refers to as "biologic disease-modifying antirheumatic drugs or biologic DMARDs".
Lastly, the PMPRB has released its 2017 Annual Report. The report includes a review of the PMPRB's regulatory activities, analyses of sales and price trends of pharmaceuticals, as well as an overview of NPDUIS and analysis of R&D expenditures. On 22 August 2018, the minister of health filed the report with the clerks of the House of Commons and the Senate.
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.